|
Match
|
Document |
Document Title |
|
|
7166300 |
Agent for inducing hair growth containing extracts of saw palmetto and swertia
The present invention consists in a composition comprising a mixture of extracts of saw palmetto and swertia , of derivatives thereof and of active components being part of said extracts. The...
|
|
|
7166605 |
Probucol nitro-derivatives
Probucol derivatives and pharmaceutical compositions containing the same to be employed in treatment or prophylaxis of diseases.
|
|
|
7163688 |
Osmotic implant with membrane and membrane retention means
An osmotic delivery system for controlled delivery of a beneficial agent includes an implantable capsule containing a beneficial agent and an osmotic engine that swells on contact with water,...
|
|
|
7163693 |
Multi-component pharmaceutical dosage form
A multi-component pharmaceutical dosage form comprising a plurality of drug substance-containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer...
|
|
|
7157101 |
Micronized eplerenone compositions
The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and...
|
|
|
7157103 |
Pharmaceutical formulation containing irritant
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating...
|
|
|
7147867 |
Dosage form comprising liquid formulation
A dosage form is disclosed comprising a drug formulation that self-emulsifies in the drug formulation.
|
|
|
7144880 |
Compositions relating to novel compounds and targets thereof
The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and...
|
|
|
7144587 |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to...
|
|
|
7141250 |
Pharmaceutical formulation containing bittering agent
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter...
|
|
|
7138137 |
Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
Provided are formulations of a stable paroxetine hydrochloride tablet comprising paroxetine hydrochloride, povidone or copovidone as a binder, and an HCl free/non-hygroscopic filler, prepared by...
|
|
|
7135465 |
Sustained release beadlets containing stavudine
Extended dosage forms of stavudine are provided comprising beadlets formed by extrusion-spheronization and coated with a seal coating. The beadlets are also coated with a modified release coating...
|
|
|
7128925 |
Device for applying active principles for pharmaceutical or cosmetic purposes
Device for applying at least one active principle, consisting of a material wherein one or several capsules or microcapsules containing the active principle(s) are distributed in a binder having a...
|
|
|
7128933 |
Composition and method for the treatment of personal odors
An orally ingestible composition for the treatment of external personal odors can include about 35% w/w to about 50% w/w of the essential oil of lavender, about 1% w/w to about 10% w/w of the...
|
|
|
7125561 |
Compartmentalized dosage form
The present invention provides provide a dosage form that prevents misuse of the medicament contained within. The dosage form contains an inactivating substance in combination with the medicament,...
|
|
|
7122207 |
High drug load acid labile pharmaceutical composition
A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a...
|
|
|
7122203 |
Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
The present invention is directed to pharmaceutical formulations containing 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho
xypheny)benzo[b]thiophene or a salt thereof; stabilized to...
|
|
|
7118762 |
Controlled release lipoic acid
A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid...
|
|
|
7115281 |
Processes for the preparation of oral dosage formulations of modafinil
The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles...
|
|
|
7115278 |
Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory...
|
|
|
7115277 |
Method for enabling delivery of an active agent
A method for enabling deliver of an active agent is provided which includes the preparation of doses of the active agent distributing educational materials and guidelines for counseling patients...
|
|
|
7108859 |
Antineoplastic product, use and formulation thereof
An antineoplastic product is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the antineoplastic product being reached in less than...
|
|
|
7105174 |
Multiple-delayed release anti-neoplastic product, use and formulation thereof
An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the C max for the anti-neoplastic product being reached...
|
|
|
7105172 |
Treatment of rosacea
Disclosed herein are methods for the treatment or prevention of rosacea in a patient, including administering a compound that inhibits one or more components of the bradykinin activation pathway in...
|
|
|
7101565 |
Probiotic/prebiotic composition and delivery method
A prebiotic, composition comprising a probiotic and prebiotic, and method of delivering a probiotic, prebiotic or composition directly into the intestinal tract of a mammal are disclosed. The...
|
|
|
7097851 |
Oral formulation for gastrointestinal drug delivery
An oral formulation for gastrointestinal drug delivery which comprises an adhesion site-controlling layer for attaching the formulation to the selected site in the digestive tract, a drug-carrying...
|
|
|
7094427 |
Combination immediate release controlled release levodopa/carbidopa dosage forms
The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated...
|
|
|
7094425 |
Enteric and colonic delivery using HPMC capsules
The invention provides a drug delivery system for delivering a drug to either the small intestine (enteric) or the colon comprising a HPMC capsule containing the drug and wherein the HPMC capsule...
|
|
|
7094426 |
Stable oral pharmaceutical dosage forms
The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such...
|
|
|
7087242 |
Subcoated simulated capsule-like medicament
A simulated capsule-like medicament comprising a subcoating of a mixture of a water-soluble, film-forming polymer, e.g. hydroxypropylmethyl cellulose and a hydrophobic plasticizer, e.g. castor oil,...
|
|
|
7083808 |
Controlled/modified release oral methylphenidate formulations
The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak...
|
|
|
7081253 |
Use of nanodispersions in pharmaceutical end formulations
A description is given of the use of a nanodispersion, which comprises
(a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations,...
|
|
|
7078054 |
Soft gelatin capsule manufacture
Soft gelatin capsules having a capsule shell comprising gelatin, plasticizers and, if desired or required, further auxiliary agents, and a capsule filling containing a solvent including a...
|
|
|
7078065 |
Composition containing asiasari radix extracts for protecting brain cells and improving memory
The present invention discloses that fractions of Asiasari Radix extract have the ability to induce neuroprotection against AMPA (-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)-induced...
|
|
|
7078045 |
Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
A pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis, which comprises 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and...
|
|
|
7074417 |
Multiple-delayed release anti-viral product, use and formulation thereof
An anti-viral product is comprised of at least three delayed release dosage forms, each of which has a different release profile, with the C max for the anti-viral product being reached in less...
|
|
|
7074427 |
Medicine, carrier for medicine, method of producing medicine, and method of tumor treatment
A medicinal preparation capable of lowering the threshold of cavitation and generating active oxygen species via acoustic cavitation caused by an ultrasound is provided. The preparation, which is...
|
|
|
7074390 |
Encapsulated dentifrice and method of use
A single use capsule containing dentifrice is disclosed. It includes toothpaste or other dentifrice enclosed in a shell or coating. The dentifrice may include miswak fibers, which acts as a natural...
|
|
|
7070965 |
Small molecule anticancer compounds and related production process
A group of specific branched-chain fatty acids, with significant anticancer effects on human and animals; methods of making using either chemical synthesis or biosynthesis methods; and methods of...
|
|
|
7070817 |
Herbal composition for treating or alleviating vascular headaches, neurological conditions and neurodegenerative diseases
The invention relates to an herbal composition comprising extract of plant Moringa Oleifera , a member of family Moringaceae, plant Piper Nigrum , a member of family Piperaceae and plant ...
|
|
|
7071228 |
Method of treating musculoskeletal and connective tissue inflammations
A method of treating said musculoskeletal and connective tissue inflammations including osteoarthritis and associated articular and periarticular inflammations, and non-articular Rheumatism...
|
|
|
7070802 |
Pharmaceutical compositions for lipophilic drugs
Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in...
|
|
|
7070800 |
Inhalable powder containing tiotropium
The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of...
|
|
|
7067153 |
Microcapsule powder
A process for making hydrophobicized powders of micro- and/or nanocapsules involving the steps of: (a) providing an aqueous polymer solution containing at least one active ingredient and at least...
|
|
|
7063857 |
Use of macrolide compounds for the treatment of dry eye
The present invention provides an agent for treating a dry eye, which contains a macrolide compound such as FK506.
|
|
|
7063861 |
Bioavailable composition of natural and synthetic HCA
The invention relates to a composition comprising hydroxycitric acid (HCA) in combination with either one or both of garcinol and anthocyanin, and its use as a weight-loss therapy in animal...
|
|
|
7060263 |
Super absorption Coenzyme Q10
An improved soft gelatin formulation and process methodology that increases single Coenzyme Q 10 molecules presented to the absorption channels of the small intestines by providing medium chain...
|
|
|
7060295 |
Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the...
|
|
|
7056495 |
Solid dose delivery vehicle and methods of making same
The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and...
|
|
|
7056530 |
Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities
A selfemulsifiable formulation comprising a lipophilic system consisting of a medium chain triglyceride of caprylic acid and capric acid, and of labrasol, wherein labrasol also serves as a...
|